Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Prostatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
2 Recruiting Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Conditions: Metastatic Prostate Carcinoma;   Metastatic Prostatic Adenocarcinoma;   Prostate Carcinoma Metastatic to the Bone
Interventions: Procedure: Robotic Assisted Radical Prostatectomy;   Procedure: Conventional open retropubic radical prostectomy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
3 Recruiting Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
Conditions: Recurrent Prostate Carcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Placebo
4 Recruiting Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
Condition: Prostate Cancer
Intervention:
5 Recruiting 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
6 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
7 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: Dendritic Cells DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
8 Unknown  Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Tesetaxel
9 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
10 Unknown  PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
Condition: Prostate Cancer
Intervention: Other: laboratory biomarker analysis
11 Unknown  DNA Changes in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Genetic: polymorphism analysis;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years